Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Patent
1995-03-28
1997-03-11
Spivack, Phyllis G.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
514639, A61K 3115
Patent
active
056101929
DESCRIPTION:
BRIEF SUMMARY
BACKGROUND OF THE INVENTION
This invention relates generally to compositions and methods useful in the treatment of certain infectious diseases. More specifically, the invention relates to compositions which inhibit proteases, such as malaria cysteine protease. Compounds that inhibit these proteases are useful in the prevention and treatment of malaria, schistosomiasis and other infectious diseases.
Proteases are involved in many important biological processes including protein turnover, blood coagulation, complement activation, hormone processing, and cancer cell invasion. Thus, they are frequently chosen as targets for drug design and discovery. The critical role certain proteases play in the life cycle of parasitic organisms also makes them attractive drug design targets for certain infectious diseases.
Schistosomiasis (bilharziasis) is a parasitic disease caused by schistosomes (blood flukes) that generally live in the veins of the gut and liver of a human host. Adult worms can survive up to 20 years. Female adult worms release thousands of eggs each day, which often find their way to tissues such as liver, brain, and lung, where they cause considerable damage by stimulating the body to form inflammation and scar tissue around them. Most eggs pass through the bladder or wall of the gut. Once outside, they hatch and infect water snails. The parasite multiplies inside the snail, giving rise to thousands of cercariae that exit the snail and swim free in search of a host in which to complete their life cycle.
Malaria is another well known infectious disease caused by protozoa of the genus Plasmodium, which are transmitted by bites of infected mosquitoes. Infection with Plasmodium falciparum, the most virulent human malarial pathogen, is estimated to be responsible for over 1 million deaths each year. The most valuable of the heretofore developed classes of antimalarial drugs are the quinoline-containing compounds, such as chloroquine and mefloquine; chloroquine has been especially effective as both a preventative and a curative. A serious problem in the treatment and control of malaria has been the increasing resistance of populations of P. falciparum to these known antimalarial drugs. In addition, reports of multi-drug resistance makes the search for novel therapies especially urgent. Thus, there remains a great need to identify new compounds that have antimalarial capabilities.
During the trophozoite stage, the parasites infect red blood cells (erythrocytes) where they reproduce asexually. At the completion of each asexual cycle, the red blood cells lyse and merozoites are released which invade new red blood cells. This cycle of lysis and re-infection is responsible for the major clinical manifestations of malaria.
Most anti-malarials are blood schizontocides which are active against the parasites during the intra-erythrocytic stage of its life cycle. Sulphones and sulphonamides inhibit the synthesis of dihydrofolic acid, while biguanides and diaminopyrimidines inhibit the synthesis of tetrahydrofolic acid. Although the mechanism of these anti-malarials is known to involve interference with the parasites' ability to synthesize nucleic acids [Bruce-Chwatt, L. J., Essential Malariology (Wiley, New York (1985))], the mechanism of action of the quinoline-containing compounds has until recently been surprisingly elusive. Recent work provides strong evidence that the quinoline derivatives work by interfering with the detoxification activity of a heme polymerase [Slater and Cerami, Nature 355, 167 (1992)].
During the erythrocytic phase, the parasites degrade hemoglobin as a primary cysteine protease involved in the degradation of hemoglobin, the parasites' primary source of amino acids [Rosenthal, P. J. et al., J. Clin. Invest. 82, 1560 (1988)]. Blocking this enzyrme with cysteine protease inhibitors (such as E-64 and Z-Phe-Arg-FMK) in culture arrests further growth and development of the parasites [Rosenthal, P. J. et al., Mol. Biochem. Parasitol. 35, 177 (1989)]. Because humans (and, probably, most other mam
REFERENCES:
Chen, et al., "Licochalone A, a New Antimalarial Agent, Inhibits In Vitro Growth of the Human Malaria Parasite Plasmodium falciparum and Protects Mice from P. yoelii infection", Antimicrobial Agents and Chemotherapy, 38(7):1470-1475 (1994).
Silfen, et al., "Bioflavonoid effects on in vitro cultures of Plasmodium falciparum. Inhibition of permeation pathways induced in the host cell membrane by intraerythrocytic parasite", Chemical Abstracts, 110(11):18, Col. 2, Abstract 87987p (1989).
Proceedings of the National Academy of Sciences, vol. 90, Issued Apr. 1993, Ring et al "Structural-Based Inhibitor Design by Using Protein Models for the Development of Antiparasitic Agents" pp. 3583-3587, See Entire Document Especially p. 3584 Figures.
Chemical Abstracts, vol. 115, No. 4, Issued 1991, Rheinberger et al. "Incorporation of Fluorescent Substances into Dental Materials for Differentiation from Surrounding Tissue," See Abstract No. 142380, Ger. Offen. DE 3939998.
Chemical Abstracts, vol. 81, No. 12, Issued 1974, Mucke, H., "Possibilities of Coloring Peracetic Acid for Skin Disinfection" See Abstract No. 68513, Pharmazie 29(3), 206-7.
Chemical Abstracts, vol. 113, No. 22, Issued 1989, Kino and Kato, "Hair Dyes Taining Water-Soluble Dyes, Carbon Black, and Nonionic Surfactants," See Abstract No. 197653, JP 01242518.
Sweeney et al. "Burger's Medicinal Chemistry" Fourth Edition, Part II. Published 1981 by John Wiley & Sons (N.Y.) pp. 342-345).
Santi et al. "Burger's Medicinal Chemistry" Fourth Edition, Part II. Published 1981 by John Wiley & Sons (N.Y.) pp. 350-351.
Rosenthal et al. The American Society for Clinical Investigation, Inc. "Antimalarial Effectis of Peptide Inhibitors of Plasmodium Falciparum Cysteine Proteinase" vol. 88, Nov. 1991, 1467-1472.
DoAmaral et al., J. Med. Chem. (12), pp. 21-25, Jan., 1969.
Cohen Fred E.
Kenyon George L.
Li Zhe
McKerrow James H.
Ring Christine S.
Spivack Phyllis G.
The Regents of the University of California
LandOfFree
Inhibitors of metazoan parasite proteases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibitors of metazoan parasite proteases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of metazoan parasite proteases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-443994